Bgb-16673

3 trials 3 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

1 Sponsors

11 Countries

Phase III

Phase I/II

Phase III: 2 Phase I/II: 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Indications tested

Marginal zone lymphoma refractory 1 Diffuse large B-cell lymphoma recurrent 1 Follicular lymphoma stage III 1 Marginal zone lymphoma recurrent 1 Waldenstrom´s macroglobulinaemia refractory 1 Follicular lymphoma stage II 1 Waldenstrom´s macroglobulinaemia recurrent 1 Follicular lymphoma stage I 1 Mantle cell lymphoma refractory 1 Richter's syndrome 1 Diffuse large B-cell lymphoma refractory 1 Mantle cell lymphoma recurrent 1

Sponsors using this IMP

BeOne Medicines AG 3

All trials

3 total

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting

2025-522860-34-00 Phase III 10 countries BeOne Medicines AG
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Phase I/II 3 countries BeOne Medicines AG
A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima… Recruiting

2024-518893-15-00 Phase III 5 countries BeOne Medicines AG

Showing 1–3 of 3 trials

← All drugs A–Z